Polfa Tarchomin is one of the oldest pharmaceutical companies in Europe. It has been operating on the market since 1823. Currently, it employs more than 950 people who work in the factory in Warsaw.The majority owner is the State Treasury.Since 1823 we take care about the health of people and are strategic manufacturer in Poland. Our production capacity is 65 million of pack per year (tablets and capsules). We have 30 production lines and produces more than 120 different forms. Polfa Tarchomin SA is a leader in the anti-infectives market. The company also holds an significant market position in the category of insulin, psychotropic drugs and dermatological preparations.All of them are available in a range of forms and sizes in order to ensure optimal medical treatment and minimal side effects experienced by the patient. Polfa Tarchomin S.A. specialises in the prescription drugs.Our medicines are produced in buildings and facilities which meet strict global requirements and quality standards.The quality of our products has been confirmed by the obtained GMP certificates.Currently the company has over 40 production lines and installations which produce drugs in pharmaceutical forms including gels, aerosols, tablets, coated tablets, capsules, ampoules, vials and insulin cartridges.The production line of oral penicillin forms, aerosol filling and freeze-drying techniques distinguish the company among other manufacturers in the industry.Polfa Tarchomin S.A. operates primarily on the Polish market. We supply hospitals and pharmacies through the network of wholesalers across the country. We also export to over 30 countries through distribution agreements and increasing our global presence.

Exclusive distributor of CosmeClinik Laboratories in POLAND & owner of the www.onko.life portal and online store for oncology patients.Our goal is to support people with special skin protection needs. We want to increase the awareness of patients, families, and adult caregivers of children about the role and importance of taking care of the skin and mucous membranes during and after oncological therapy. At ONKO.life, we offer modern cosmetic products that improve the quality of life of patients. At LOVE.life, we want to provide knowledge and ready-made solutions in the form of educational and communication materials, meetings with specialists, webinars, and online classes to draw attention to the fact that the special needs of cancer patients require special behaviors and solutions. Effective support and daily care improve overall well-being and well-being, which are part of the treatment and recovery process. Providing adequate nutrition, supplementation and rest is particularly important during treatment, recovery, and daily duties. The aspect of consciously minimizing the risk related to environmental factors plays an important role.Join us and support patients with ONKO.life.ONKO.life & LOVE.life From patient to patient#lovelife

The company has been operating since 2015 through three divisions: Consumer Healthcare (CHC), Hospital Medicines and Unregistered Medicines. Our product portfolio of Medicines, Food Supplements and Medical Devices covers a broad range of therapeutic indications, including Women’s Healthcare, Pain & Inflammation, Pediatrics, Neurology, Oncology, Gastroenterology, Urology, Hematology and Dermatology.

Polish biotech, previously Biomed Lublin S.A. with long manufacturing traditions. Present on the Polish and international markets since 1944.• MoH only supplier of BCG vaccine and Gamma Anty-D products• Biomed Lublin participated in „Research on production of specific human immunoglobulin from plasma of donors after SARS-CoV-2 viral infection and its therapeutic application in patients with COVID 19". Within the framework of the project, Biomed Lublin was a supplier and responsible of the preparation and production of anti-SARS-CoV-2 immunoglobulin• ~250 staff mainly in production • Turnover ~ 10m €• Responsible for significant BCG production sites extension with the investment budget ~ 35m € - (around 50% covered by EU funds)• Secured financing for new R&D center (under construction) - EU funds, equity, loans and operational business.• Biomed Lublin products currently available on 30+ markets via distributors

• Senior Management Team Member• CVRM BU promoted portfolio – anti-platelet and anti-diabetes products - BRILIQUE, FORXIGA & XIGDUO, BYDUREON• Responsible for 35m$ - sales business and team of 78 people• FORXIGA reimbursement in 11’19. First innovative oral therapy for T2D patients over last decade

Country Manager Eli Lilly Polska sp. z o.o. President of the BoardLead and manage entity (USD 60m sales) Coordinate and moderate cross-business unit alignment within Eli Lilly (CNS, Diabetes, Urology, Oncology). INFARMA Supervisory Board Member

Business Unit Director, DiabetesLead and manage Diabetes Business Unit8 direct reports, ca. 70 total reportsResponsible for USD 45m turnoverReporting to regional BU Senior Leader

• Management Committee Member Bayer sp. z o.o., Procurer• Full P&L responsibility, reporting to regional headquarter in Basel, Switzerland • In all 4 consecutive years 2007-2011 organization overachieved business targets with 40 to 80% growth rate each year.• Developed business from 1 to 25 million Euro in 5 years: fastest growing BGM company in Poland